查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1620332

全球術後疼痛治療藥物市場規模：依藥物類別、給藥途徑、分銷管道、地區、範圍和預測

Global Postoperative Pain Therapeutics Market Size By Drug Class, By Route Of Administration, By Distribution Channel, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

術後疼痛治療藥物市場規模及預測

2023年術後疼痛治療市場規模為121.6億美元，預計2024年至2031年複合年增長率為3.89%，到2031年預計將達到164.9億美元。術後止痛藥物是指控制患者在手術後所經歷的疼痛的醫療介入和治療。術後止痛藥旨在減輕疼痛、促進癒合併改善術後整體復原。此類治療包括各種藥理學和非藥理學技術，以適應每位患者的特定需求和所進行的手術類型。

鴉片類藥物、非類固醇類抗發炎藥 (NSAID) 和局部麻醉藥是藥物治療中常用的止痛藥。非藥物治療包括物理治療、針灸和放鬆練習。

此外，術後止痛藥廣泛用於各種醫學專業和外科手術，從小型門診手術到更具侵入性的手術。

術後疼痛治療藥物市場動態

塑造術後疼痛治療市場的關鍵市場動態

主要市場推動因素

手術技術的提升：

由於人口老化、慢性疾病和外科手術技術的發展，全世界外科手術的增加增加了術後止痛藥物以有效控制術後疼痛的需求。

關於疼痛管理的看法和期望：

患者和醫療保健專業人員越來越意識到適當疼痛管理的必要性。因此，患者對舒適恢復時間的期望增加，從而增加了對先進術後止痛藥物的需求。

藥品創新及審核：

新的有效疼痛治療方法（包括非鴉片類藥物替代品）的開發和批准是一個重要的驅動力。藥物傳遞系統的創新也推動了市場的發展，這些創新可以提供更長時間的疼痛緩解且副作用最小。

政府與醫療政策：

鼓勵醫療機構實施有效疼痛管理標準的政府法規和指南刺激了先進治療藥物的使用。有利於疼痛管理藥物和治療的報銷法規正在推動術後止痛藥物市場的發展。

主要課題

鴉片類藥物危機與監管：

由於鴉片類藥物危機，有關鴉片類藥物處方的法律變得更加嚴格，為市場參與者設置了障礙。對非鴉片類止痛藥的需求不斷增長，但開發與鴉片類藥物一樣有效的替代品卻很複雜。

止痛藥物的副作用：

許多術後鎮痛藥物有噁心、嘔吐和便秘等副作用，並且可能引起毒性，因此不鼓勵使用。開發副作用較少的藥物也是市場開發的重要課題。

臨床和監管障礙：

將創新的疼痛管理產品推向市場需要廣泛的臨床試驗和監管部門的批准。這些過程既耗時又昂貴，為新藥物和技術進入術後疼痛治療市場設置了重大障礙。

主要趨勢：

對非鴉片類藥物的需求不斷增長：

對鴉片類藥物成癮的擔憂正在推動人們轉向非鴉片類藥物治療。因此，製藥公司正在開發非成癮性疼痛管理治療方法，可以有效治療術後疼痛，且沒有鴉片類藥物的風險。

多模式疼痛管理的興起：

"多模式疼痛管理" 結合了多種方法和藥物來治療疼痛，在市場上越來越受歡迎。此方法旨在改善疼痛緩解並最大限度地減少副作用，從而加快患者康復速度並縮短住院時間。

門診手術中心的成長：

由於門診手術中心 (ASC) 的發展，對有效的術後止痛藥物的需求量很大。ASC 為醫院手術提供了一種經濟高效的替代方案，專注於縮短患者康復時間並增強疼痛管理方案。

藥物輸送系統的進展：

為了提高術後疼痛管理的有效性和便利性，人們越來越重視開發新的藥物傳遞系統，例如透皮貼片和植入裝置。這些技術可調節藥物的釋放，因此無需頻繁給藥即可持續緩解疼痛。

術後疼痛治療藥物市場的區域分析

術後疼痛治療藥物市場的詳細區域分析

北美：

根據驗證市場研究，預計北美將在預測期內主導術後疼痛治療藥物市場。北美由於其先進的醫療基礎設施和患者獲得醫療護理的機會而進行了大量的外科手術，這推動了對術後止痛藥物的需求，以成功地管理康復。

該地區目前正經歷鴉片類藥物危機，非鴉片類藥物疼痛治療方案正受到廣泛關注。監管機構和醫療保健利益相關者致力於尋找更安全、更有效的方法來控制術後疼痛而不助長成癮。

北美主要製藥公司和研究機構的存在推動了創新疼痛管理藥物（包括非鴉片類藥物和新型藥物輸送方法）的開發，正在推動市場成長。

此外，隨著北美門診手術中心（ASC）的擴張以及具有成本效益和高效的手術護理，術後疼痛管理選項可確保及時康復並需要加強患者滿意度。

亞太地區：

在市場估計和預測期內，亞太地區預計將以最高的複合年增長率成長。亞太地區的醫療基礎設施（包括醫院和手術中心）正在顯著增長，以適應越來越多需要適當術後疼痛治療的外科手術。

在日本、中國和印度等國家，更容易患慢性病的老齡化人口不斷增加，外科手術的需求也在增加，從而增加了對治療術後疼痛的藥物的需求。

醫療保健專業人員和患者越來越意識到適當疼痛管理的必要性，推動了該地區術後疼痛藥物市場對先進治療的需求。

此外，亞太地區的經濟發展正在增加醫療保健支出和醫學研究投資，促進先進術後疼痛管理方案的發展。

歐洲：

歐洲對疼痛管理藥物（尤其是鴉片類藥物）的使用有嚴格的規定，並且對創新且安全的術後疼痛治療的需求不斷增長。

歐洲每年進行大量的選擇性和非選擇性手術，因此對有效的術後疼痛管理解決方案的需求很高，以促進患者康復並縮短住院時間。

為了全面緩解術後疼痛，歐洲醫療保健系統越來越多地實施結合藥物和非藥物治療的多模式疼痛治療策略。

此外，歐洲醫療保健創新舉措，例如創新藥物輸送方法和非阿片類藥物的開發，透過提供有效且對患者友好的替代方案，正在推動術後疼痛治療市場的成長。

目錄

第1章全球術後疼痛治療藥物市場：簡介

  • 市場概況
  • 調查範圍
  • 先決條件

第 2 章執行摘要

第3章 驗證市場研究研究方法

  • 數據挖掘
  • 確認
  • 初步面試
  • 數據源列表

第4章 全球術後疼痛治療藥物市場展望

  • 概述
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 波特的五力模型
  • 價值鏈分析

第5章全球術後疼痛治療藥物市場：依藥物類別

  • 概述
  • 鴉片類藥物
  • 非類固醇類抗發炎藥 (NSAID)
  • 局部麻醉劑
  • 三環抗憂鬱藥
  • 抗癲癇藥
  • 其他

第6章全球術後疼痛治療市場：依給藥途徑分類

  • 概述
  • 口服劑
  • 肌肉內
  • 靜脈給藥
  • 其他

第7章全球術後疼痛治療藥物市場：依通路劃分

  • 概述
  • 醫院藥房
  • 零售藥店
  • 網上藥店
  • 其他

第8章全球術後疼痛治療藥物市場：按地區

  • 概述
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 亞太其他地區
  • 世界其他地區
    • 拉丁美洲
    • 中東/非洲

第9章 全球術後疼痛治療藥物市場：競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第10章 公司簡介

  • AbbVie
  • Johnson & Johnson
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Merck & Co. Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca plc
  • Eli Lilly and Company
  • GlaxoSmithKline plc

第11章 主要進展

  • 產品發佈/開發
  • 併購
  • 業務拓展
  • 夥伴關係和聯盟

第12章附錄

  • 相關研究
簡介目錄
Product Code: 11282

Postoperative Pain Therapeutics Market Size And Forecast

Postoperative Pain Therapeutics Market size was valued at USD 12.16 Billion in 2023 and is projected to reach USD 16.49 Billion by 2031 , growing at a CAGR of 3.89% from 2024 to 2031. Postoperative pain therapeutics refers to medical interventions and treatments used to manage pain experienced by patients following surgical procedures. Postoperative pain therapeutics aim to reduce suffering, increase healing, and improve overall recovery after surgery. These therapeutics include a variety of pharmacological and non-pharmacological techniques that are adapted to each patient's specific needs and the type of operation performed.

Opioids, nonsteroidal anti-inflammatory medicines (NSAIDs), and local anesthetics are popular analgesics used in pharmacological therapies. Non-pharmacological therapies include physical therapy, acupuncture, and relaxation exercises.

Furthermore, postoperative pain therapeutics are used in a wide range of medical specializations and surgical procedures, from small outpatient procedures to more invasive operations.

Postoperative Pain Therapeutics Market Dynamics

The key market dynamics that are shaping the Postoperative Pain Therapeutics Market include:

Key Market Drivers

Rising Surgical Procedures:

The global increase in surgical procedures due to aging populations, chronic diseases, and technical developments in surgery techniques is driving the need for postoperative pain therapeutics to effectively manage pain after surgery.

Awareness and Expectation for Pain Management:

Patients and healthcare providers are becoming increasingly aware of the necessity of proper pain management. As a result, advanced postoperative pain therapeutics are in high demand due to rising patient expectations for comfortable recovery times.

Pharmaceutical Innovations and Approvals:

The development and approval of new and effective pain treatment medications, including non-opioid alternatives, are important drivers. Drug delivery system innovations that provide longer pain relief while minimizing negative effects also helping drive market.

Government and Healthcare Policies:

Government rules and guidelines encouraging effective pain management standards in healthcare facilities stimulate the use of sophisticated therapeutics. Reimbursement rules that favor pain management medications and therapies are propelling the Postoperative Pain Therapeutics Market.

Key Challenges:

Opioid Crisis and Regulation:

The opioid crisis has resulted in stringent opioid prescription laws, which pose hurdles for players in the market. The demand for non-opioid pain treatment solutions is growing, but creating alternatives that are as effective as opioids is complicated.

Side Effects of Pain Management Drugs:

Many postoperative pain management medicines have side effects, such as nausea, vomiting, constipation, and the potential for addiction is discouraging their usage. Developing medications with minimal side effects is also an important challenge in the market.

Clinical and Regulatory Hurdles:

Bringing innovative pain management products to market needs extensive clinical testing and regulatory authorization. These processes are time-consuming and costly, creating significant barriers to the entry of novel medications and technologies into the Postoperative Pain Therapeutics Market.

Key Trends:

Increasing Demand for Non-Opioid Medications:

Concerns about opioid addiction are driving a huge shift towards non-opioid therapies. Thus, pharmaceuticals are developing non-addictive pain management treatments that effectively cure postoperative pain without the hazards of opioids.

Rise of Multimodal Pain Management:

Multimodal pain management, which combines several approaches and drugs to treat pain, is becoming increasingly popular in the market. This method attempts to improve pain relief and minimize adverse effects, resulting in faster patient recovery and shorter hospital stays.

Growth in Ambulatory Surgical Centers:

Effective postoperative pain therapeutics are in high demand due to the growth of ambulatory surgical centers (ASCs). ASCs provide a cost-effective alternative to hospital-based surgeries, focusing on reducing patient recovery time and enhancing pain management protocols.

Advancements in Drug Delivery Systems:

There is a rising emphasis on creating novel medication delivery systems, such as transdermal patches and implanted devices, to improve the efficacy and convenience of post-operative pain management. These technologies provide regulated medication release, resulting in constant pain relief without frequent dosage.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Postoperative Pain Therapeutics Market Regional Analysis

Here is a more detailed regional analysis of the Postoperative Pain Therapeutics Market:

North America:

According to Verified Market Research, North America is estimated to dominate the Postoperative Pain Therapeutics Market during the forecast period. North America has an important number of surgical procedures due to sophisticated healthcare infrastructure and patient access to medical care, driving the demand for postoperative pain therapeutics to successfully manage recovery.

With the present opioid crisis in this region, there is a tremendous push for non-opioid pain management alternatives. Regulatory agencies and healthcare practitioners are concentrating on safer, more effective ways to manage postoperative pain without contributing to addiction.

The presence of major pharmaceutical companies and research institutions in North America promotes the development of innovative pain management medicines, such as non-opioid medications and novel drug delivery methods is propelling the growth of the market.

Furthermore, the expansion of ambulatory surgical centers (ASCs) in North America, which provide cost-effective and efficient surgical treatment is demanding enhanced postoperative pain management options to ensure timely recovery and patient satisfaction.

Asia Pacific:

Asia Pacific is estimated to grow at the highest CAGR within the market during the forecast period. Asia Pacific is experiencing tremendous growth in healthcare infrastructure, including hospitals and surgical centers, to accommodate an increasing number of surgical procedures that necessitate adequate postoperative pain treatment.

The growing older population in countries such as Japan, China, and India, which are more prone to chronic illnesses necessitate surgical procedures, thereby boosting demand for postoperative pain therapeutics.

Healthcare professionals and patients are becoming more conscious of the necessity of appropriate pain management, driving up demand for sophisticated treatments in the Postoperative Pain Therapeutics Market in this region.

Furthermore, economic development in the Asia-Pacific region has resulted in increasing healthcare spending and medical research investments, facilitating access to the development of advanced postoperative pain management options.

Europe:

Europe's stringent regulatory framework for pain management medications, particularly opioid use, fuels demand for innovative and safer postoperative pain therapies.

With a significant number of elective and non-elective surgeries conducted each year, Europe has a high demand for efficient postoperative pain management solutions to improve patient recovery and shorten hospital stays.

To provide comprehensive pain relief following surgery, European healthcare systems are increasingly implementing multimodal pain treatment strategies that combine pharmaceutical and nonpharmacological approaches.

Furthermore, Europe's dedication to healthcare innovation, which includes the development of innovative drug delivery methods and non-opioid drugs, helps to drive market growth for postoperative pain treatments by providing effective and patient-friendly alternatives.

Postoperative Pain Therapeutics Market: Segmentation Analysis

The Global Postoperative Pain Therapeutics Market is segmented based on Drug Class, Route Of Administration, Distribution Channel, And Geography.

Postoperative Pain Therapeutics Market, By Drug Class

  • Opioids
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Local Anesthetics
  • Tricyclic Antidepressants
  • Antiepileptic Drugs
  • Others

Based on Drug Class, the market is segmented into Opioids, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Local Anesthetics, Tricyclic Antidepressants, Antiepileptic Drugs, and Others. The opioids segment is estimated to dominate the Postoperative Pain Therapeutics Market due to their effectiveness in managing moderate to severe pain. Despite increasing concerns about addiction and the search for non-opioid alternatives, opioids remain popular in the postoperative setting due to their superior efficacy in treating acute pain. Opioids are used by healthcare practitioners for acute pain treatment after surgery, especially when the intensity of the pain exceeds the analgesic capacity of NSAIDs or local anesthetics.

Postoperative Pain Therapeutics Market, By Route Of Administration

  • Oral
  • Intramuscular
  • Intravenous
  • Others

Based on the Route Of Administration, the market is segmented into Oral, Intramuscular, Intravenous, and Others. The intravenous segment is estimated to dominate the Postoperative Pain Therapeutics Market during the forecast period. The intravenous route is preferable in hospitals due to its rapid start of action, accurate dosage control, and capacity to offer continuous pain relief, all of which are critical for managing acute postoperative pain. Furthermore, intravenous delivery is extremely beneficial for individuals who are unable to take oral drugs due to postoperative restrictions or nausea. The efficiency, control, and quick comfort given by the intravenous injection make it an essential component of postoperative therapy, assuring its market domination.

Postoperative Pain Therapeutics Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Based on the Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. The hospital pharmacies segment is estimated to dominate the market over the forecast period. This dominance is due to hospital pharmacies' direct involvement in the patient care process, particularly during the early postoperative period. Hospital pharmacies play an important role in the healthcare delivery system, ensuring that critical pain management drugs are available quickly after surgical procedures. This segment's popularity is bolstered by the high volume of surgeries conducted in hospitals, where thorough pain management protocols are vital to patient care, making hospital pharmacies an important component of the Postoperative Pain Therapeutics Market.

Key Players

  • The " Global Postoperative Pain Therapeutics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • AbbVie, Johnson & Johnson, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Eli Lilly and Company, GlaxoSmithKline plc, Baxter International Inc., Zimmer Biomet Holdings Inc., Boston Scientific Corporation, Medtronic plc, Stryker Corporation, Becton, Dickinson and Company, Smith & Nephew plc, and Altaris Therapeutics Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In February 2024, Pacira BioSciences announced positive findings from a Phase 3 trial of its long-acting local anaesthetic EXPAREL(R) in patients having bunionectomy surgery. The trial attained its primary goal of showing a statistically significant reduction in pain levels when compared to placebo.
  • In January 2024, Collegium Pharmaceutical introduced its new Xtampza ER(R) (oxycodone hydrochloride) extended-release tablets in a new 20mg dosing strength. This broadens the product portfolio for treating moderate-to-severe chronic pain.
  • In January 2024, Grunenthal demonstrated positive results from a Phase 2 research of its new nerve growth factor (NGF) inhibitor, Qsymia(R) (resiniferatoxin), for the treatment of post-surgical neuropathic pain. The findings revealed significant increases in pain levels and quality of life when compared to placebo.
  • In January 2024, Aprecia Pharmaceuticals expanded its Sprintec(R) (Aprecia Melt) line of fast-dissolving sublingual films with the introduction of Aprecia Melt Zuplenz(R) (ondansetron) for the prevention and management of nausea and vomiting associated with surgery.
  • In January 2024, Xeris Pharmaceuticals published findings from a Phase 2 study of GLYENA(R), a novel sustained-release local anaesthetic, for the treatment of postherpetic neuralgia. The findings revealed significant increases in pain levels and quality of life when compared to placebo.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET, BY DRUG CLASS

  • 5.1 Overview
  • 5.2 Opioids
  • 5.3 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • 5.4 Local Anesthetics
  • 5.5 Tricyclic Antidepressants
  • 5.6 Antiepileptic Drugs
  • 5.7 Others

6 GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1 Overview
  • 6.2 Oral
  • 6.3 Intramuscular
  • 6.4 Intravenous
  • 6.5 Others

7 GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 7.1 Overview
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies
  • 7.5 Others

8 GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 AbbVie
    • 10.1.1 Company Overview
    • 10.1.2 Company Insights
    • 10.1.3 Business Breakdown
    • 10.1.4 Product Benchmarking
    • 10.1.5 Key Developments
    • 10.1.6 Winning Imperatives
    • 10.1.7 Current Focus & Strategies
    • 10.1.8 Threat from Competition
    • 10.1.9 SWOT Analysis
  • 10.2 Johnson & Johnson
    • 10.2.1 Company Overview
    • 10.2.2 Company Insights
    • 10.2.3 Business Breakdown
    • 10.2.4 Product Benchmarking
    • 10.2.5 Key Developments
    • 10.2.6 Winning Imperatives
    • 10.2.7 Current Focus & Strategies
    • 10.2.8 Threat from Competition
    • 10.2.9 SWOT Analysis
  • 10.3 Pfizer Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Company Insights
    • 10.3.3 Business Breakdown
    • 10.3.4 Product Benchmarking
    • 10.3.5 Key Developments
    • 10.3.6 Winning Imperatives
    • 10.3.7 Current Focus & Strategies
    • 10.3.8 Threat from Competition
    • 10.3.9 SWOT Analysis
  • 10.4 Teva Pharmaceutical Industries Ltd.
    • 10.4.1 Company Overview
    • 10.4.2 Company Insights
    • 10.4.3 Business Breakdown
    • 10.4.4 Product Benchmarking
    • 10.4.5 Key Developments
    • 10.4.6 Winning Imperatives
    • 10.4.7 Current Focus & Strategies
    • 10.4.8 Threat from Competition
    • 10.4.9 SWOT Analysis
  • 10.5 Novartis AG
    • 10.5.1 Company Overview
    • 10.5.2 Company Insights
    • 10.5.3 Business Breakdown
    • 10.5.4 Product Benchmarking
    • 10.5.5 Key Developments
    • 10.5.6 Winning Imperatives
    • 10.5.7 Current Focus & Strategies
    • 10.5.8 Threat from Competition
    • 10.5.9 SWOT Analysis
  • 10.6 Merck & Co. Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Insights
    • 10.6.3 Business Breakdown
    • 10.6.4 Product Benchmarking
    • 10.6.5 Key Developments
    • 10.6.6 Winning Imperatives
    • 10.6.7 Current Focus & Strategies
    • 10.6.8 Threat from Competition
    • 10.6.9 SWOT Analysis
  • 10.7 F. Hoffmann-La Roche Ltd.
    • 10.7.1 Company Overview
    • 10.7.2 Company Insights
    • 10.7.3 Business Breakdown
    • 10.7.4 Product Benchmarking
    • 10.7.5 Key Developments
    • 10.7.6 Winning Imperatives
    • 10.7.7 Current Focus & Strategies
    • 10.7.8 Threat from Competition
    • 10.7.9 SWOT Analysis
  • 10.8 AstraZeneca plc
    • 10.8.1 Company Overview
    • 10.8.2 Company Insights
    • 10.8.3 Business Breakdown
    • 10.8.4 Product Benchmarking
    • 10.8.5 Key Developments
    • 10.8.6 Winning Imperatives
    • 10.8.7 Current Focus & Strategies
    • 10.8.8 Threat from Competition
    • 10.8.9 SWOT Analysis
  • 10.9 Eli Lilly and Company
    • 10.9.1 Company Overview
    • 10.9.2 Company Insights
    • 10.9.3 Business Breakdown
    • 10.9.4 Product Benchmarking
    • 10.9.5 Key Developments
    • 10.9.6 Winning Imperatives
    • 10.9.7 Current Focus & Strategies
    • 10.9.8 Threat from Competition
    • 10.9.9 SWOT Analysis
  • 10.10 GlaxoSmithKline plc
    • 10.10.1 Company Overview
    • 10.10.2 Company Insights
    • 10.10.3 Business Breakdown
    • 10.10.4 Product Benchmarking
    • 10.10.5 Key Developments
    • 10.10.6 Winning Imperatives
    • 10.10.7 Current Focus & Strategies
    • 10.10.8 Threat from Competition
    • 10.10.9 SWOT Analysis

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research